Log in to search using one of your social media accounts:

 

New Canon Digital Radiography Systems to be Showcased at RSNA Annual Meeting, Highlighting Ergonomic Design
Canon U.S.A. also announces new version of software to streamline workflow for Canon detectors MELVILLE, N.Y., Nov. 22, 2017 -- (Healthcare Sales & Marketing Network) -- Leveraging the rich history of high-quality imaging and innovation of its parent c... Devices, Radiology, Product Launch Canon, CXDI, digital radiography (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 22, 2017 Category: Pharmaceuticals Source Type: news

Ampio Announces Publication of Ampion(TM) Treatment of Severe Osteoarthritis of the Knee as a Feature Article in Orthopedics Peer-Reviewed Journal
ENGLEWOOD, Colo., Nov. 22, 2017 -- (Healthcare Sales & Marketing Network) -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript entitled: "LMWF-5A for the Treatment of Severe Osteoarthritis of the Knee: Integrated Analysis... Biopharmaceuticals, Orthopaedic Ampio Pharmaceuticals, osteoarthritis, Ampion (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 22, 2017 Category: Pharmaceuticals Source Type: news

Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O'Brien as Vice President of Market Access
JERSEY CITY, N.J., Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the appointment of Kevin O'Brien as Vice President of Market Access and a member of the organization's executive le... Biopharmaceuticals, Personnel Mitsubishi Tanabe Pharma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2017 Category: Pharmaceuticals Source Type: news

MiMedx Provides Update On Its Reimbursement Coverage
MARIETTA, Ga., Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts ... Regenerative Medicine, Reimbursement MiMedx, EpiFix, Venous Leg Ulcer, Diabetic Foot Ulcer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2017 Category: Pharmaceuticals Source Type: news

Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy
SAN FRANCISCO, Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatenin... Biopharmaceuticals Audentes Therapeutics, X-Linked Myotubular Myopathy, RECENSUS Study (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2017 Category: Pharmaceuticals Source Type: news

Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Company to Host Conference Call at 8:30 a.m. ET Today FREMONT, Calif., Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second... Biopharmaceuticals Ardelyx, tenapanor, hyperphosphatemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2017 Category: Pharmaceuticals Source Type: news

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda(R) (Lurasidone Hydrochloride) in Europe
TOKYO and ROME, November 21, 2017 -- (Healthcare Sales & Marketing Network) -- Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; hereinafter "Sumitomo Dainippon Pharma") and Angelini S.p.A. (Head Office: Rom... Biopharmaceuticals, Licensing, Distribution Sumitomo Dainippon Pharma, Angelini S.p.A, Latuda, lurasidone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2017 Category: Pharmaceuticals Source Type: news

Paradigm Spine, LLC Announces - Highmark, Inc. Is 1st Private Payor To Issue Exclusive Positive Coverage Policy For coflex(R) Interlaminar Stabilization(R) Treatment Of Lumbar Spinal Stenosis
Lumbar Spinal Stenosis Affects 1.6 million U.S. Patients Annually Medical coverage policy issued by Highmark, Inc. and affiliates operating health insurance plans for 5.0 million members in Pennsylvania (PA), West Virginia (WV), and Delaware (DE) Exc... Devices, Orthopaedic, Neurosurgery, Reimbursement Paradigm Spine, coflex, Interlaminar Stabilization, Spinal Stenosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves Kaléo's AUVI-Q(R) (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children
First and only epinephrine auto-injector (EAI) approved with a needle length and dose specifically designed for infants and children weighing 16.5 to 33 pounds (7.5 to 15 kilograms) Anaphylaxis and food allergies increasing in children; previously no EA... Biopharmaceuticals, Devices, Drug Delivery, FDA Kaléo, AUVI-Q, Epinephrine, auto-injector (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

Volpara Receives Regulatory Clearances in Japan and Taiwan
WELLINGTON, New Zealand, Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Volpara Solutions announced today that it has received regulatory clearances for its suite of quantitative breast imaging tools in Japan and Taiwan. In Japan, the full Vol... Devices, Radiology, Oncology, Regulatory Volpara Solutions, VolparaDensity, breast imaging (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

Getinge announces installation of 1,000th Hybrid operating room worldwide
As a pioneer in the design and installation of Hybrid ORs, Getinge is a trusted partner that offers a full range of products for these multi-disciplinary spaces WAYNE, N.J., Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Getinge, a leading ... Devices, Cardiology, Radiology Getinge, Hybrid OR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

HeartStitch(R) "Sutures The Future" at the TCT in Denver, Colorado
HeartStitch® Showcases its Suture-Based Technologies at US Largest Structural Heart Conference TCT 2017 PROVIDES CLEAR FOCUS ON KEY MARKET SEGMENTS, PFO, MITRAL AND TRICUSPID VALVE STRUCTURAL HEART TREATMENTS FOUNTAIN VALLEY, Calif., Nov. 20, 201... Devices, Cardiology Nobles Medical Technology, HeartStitch, NobleStitch (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivi... Biopharmaceuticals, FDA, Licensing United Therapeutics, Adcirca, tadalafil, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -... Biopharmaceuticals, Devices, Drug Delivery, Product Launch Amgen, ENBREL Mini, Enbrel, Etanercept, autoinjector (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

ResMed Elects Karen Drexler to its Board of Directors
A champion of women in leadership, Drexler brings wealth of experience at both commercial-stage and start-up medtech and healthcare companies Also at annual meeting of shareholders, long-serving Director Chris Roberts announced his retirement SAN DIE... Devices, Personnel ResMed, sleep apnea, chronic obstructive pulmonary disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document
MiMedx reiterates Fourth Quarter and Full Year 2017 Guidance MARIETTA, Ga., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and th... Regenerative Medicine, FDA MiMedx, EpiFix, Venous Leg Ulcer, Diabetic Foot Ulcer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
SILVER SPRING, Md., Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hem... Biopharmaceuticals, FDA Genentech, Hemlibra, emicizumab, hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

FDA Announces Comprehensive Regenerative Medicine Policy Framework
Framework aims to spur innovation, efficient access to potentially transformative products, while ensuring safety and efficacy SILVER SPRING, Md., Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Today the U.S. Food and Drug Administration an... Regenerative Medicine, FDA U.S. Food and Drug Administration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development
NEW YORK and TEL AVIV, Israel, Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- RDD Pharma, a leader in developing treatments for lower gastro-intestinal disorders, has raised $9.5M in Series B funding, including $6M from two new investors, Phar... Biopharmaceuticals, Gastroenterology, Venture Capital RDD Pharma, anal fissure, fecal incontinence, colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
FRANKLIN LAKES, N.J., Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Sy... Devices, Interventional, Acquisitions BD , Merit Medical Systems, C. R. Bard, needle biopsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
STOCKHOLM, Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been randomised in the phase 3 study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatm... Biopharmaceuticals Swedish Orphan Biovitrum, Sobi , anakinra, Still's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
NEW HAVEN, Conn., Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced that it is completing enrollment today in the first of its two registrational Phase 3 clinical trials, Study B... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, rimegepant, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2017 Category: Pharmaceuticals Source Type: news

Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by t... Biopharmaceuticals, Cardiology, FDA Noden Pharma, Tekturna, aliskiren, Hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

Arterys Completes Series B to Accelerate Product Commercialization
Imaging analytics leader closes $30M round led by Temasek, along with Varian, Northwell Health Ventures, NewYork-Presbyterian, GE Ventures and several leading venture investors SAN FRANCISCO, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- A... Devices, Radiology, Venture Capital Arterys, imaging analytics, medical image analytics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

Outpost Medicine Appoints Scott Byrd as Chief Executive Officer and Raises $20 Million in Series A Financing Extension
New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome INDIANAPOLIS and LONDON, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Outpost ... Biopharmaceuticals, Venture Capital, Personnel Outpost Medicine, Irritable Bowel Syndrome, Overactive Bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs
The largest investment round for a private medical device company in Europe in 2017 EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 -- (Healthcare Sales & Marketing Network) -- Xeltis, a clinical-stage medical device company pioneering a resto... Devices, Cardioloy, Venture Capital Xeltis , Endogenous Tissue Restoration, heart valve therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news

NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
AMES, Iowa, Nov. 14, 2017 -- (Healthcare Sales & Marketing Network) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all... Biopharmaceuticals, Oncology, Personnel NewLink Genetics, IDO pathway inhibitor, Indoximod (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 14, 2017 Category: Pharmaceuticals Source Type: news

FDA warns about illegal use of injectable silicone for body contouring and associated health risks
SILVER SPRING, Md., Nov. 14, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today issued a safety communication to warn consumers and health care practitioners about the serious injuries and disfigurement that can r... Devices, Dermatology, FDA FDA, injectable silicone, dermal filler (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 14, 2017 Category: Pharmaceuticals Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA advisory about deadly risks associated with Kratom
SILVER SPRING, Md., Nov. 14, 2017 -- (Healthcare Sales & Marketing Network) -- The FDA is concerned about harmful unapproved products that have been crossing our borders in increasing numbers. The agency has a public health obligation to act when we see p... Biopharmaceuticals, FDA FDA, Kratom (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 14, 2017 Category: Pharmaceuticals Source Type: news

Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Theravance Biopharma, Inc.... Biopharmaceuticals, FDA Theravance Biopharma, Mylan, Revefenacin, Chronic Obstructive Pulmonary Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2017 Category: Pharmaceuticals Source Type: news

Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors
Simpson brings 22 years of industry experience to Spruce, a clinical-stage biotech developing a novel treatment for congenital adrenal hyperplasia, a rare endocrine disease SAN FRANCISCO, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Spruc... Biopharmaceuticals, Personnel Spruce Biosciences, adrenal hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2017 Category: Pharmaceuticals Source Type: news

EMD Serono Receives FDA Approval for New GONAL-f(R) RFF Redi-ject(R) Pen
Redesigned pen injector developed based on insights of healthcare professionals and fertility patients ROCKLAND, Mass., Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germ... Biopharmaceuticals, Drug Delivery, FDA EMD Serono, Merck KGaA, GONAL-f RFF, Redi-ject, follitropin alfa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2017 Category: Pharmaceuticals Source Type: news

PlaqueTec Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as Chief Executive Officer
Life Sciences Leader to Guide Company through its Next Growth Phase and Product Launch in 2018 CAMBRIDGE, England, November 13, 2017 -- (Healthcare Sales & Marketing Network) -- The Board of Directors of PLAQUETEC LTD ('PlaqueTec') today announced the ... Devices, Diagnostics, Cardiology, Personnel PlaqueTec, Liquid Biopsy, coronary artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2017 Category: Pharmaceuticals Source Type: news

Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks DUBLIN, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN) today announce... Biopharmaceuticals, Neurology, FDA Allergan, VRAYLAR, cariprazine, Schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2017 Category: Pharmaceuticals Source Type: news

Elanco, Aratana Announce Positive Opinion on GALLIPRANT(R) (grapiprant tablets) in Europe
LEAWOOD, Kan., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency's (EMA) Committee f... Biopharmaceuticals, Regulatory Elanco Animal Health, Eli Lilly, Aratana Therapeutics, GALLIPRANT, arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder THOUSAND OAKS, Calif., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the C... Biopharmaceuticals, Regulatory Amgen, Nplate, romiplostim, thrombocytopenic purpura (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the Commit... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Avastin, bevacizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
LAVAL, Quebec, Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has completed the sale of the Obagi Med... Biopharmaceuticals, Mergers & Acquisitions Valeant Pharmaceuticals, Obagi Medical, Haitong International (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development
STOCKHOLM, Sweden , Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Medivir AB (NASDAQ: MVIR) (Stockholm: MVIR) announces today the appointment of Christina Herder, as Executive Vice President, Strategic Business Development effective December... Biopharmaceuticals, Oncology, Personnel Medivir AB (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2017 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Vision Announces TearScience LipiScan(R) and LipiFlow(R) Now Available in More Than 800 Eye Care Practices to Image Meibomian Glands and Treat Meibomian Gland Dysfunction
Meibomian Gland Dysfunction (MGD) is a primary cause of dry eye disease, which impacts more than 340 million people globally LipiScan® and LipiFlow® technologies offer rapid, effective solutions for optometry and ophthalmology practices in North... Devices, Ophthalmology, Product Launch Johnson & Johnson, TearScience, LipiScan, LipiFlow, Meibomian Gland, dry eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Vision Announces Series of Product Milestones and Launches Across Portfolio at American Academy of Ophthalmology 2017 Meeting
More than 350,000 TECNIS Symfony® and Symfony® Toric lenses, the first-ever extended depth of focus presbyopia correcting lenses, now in use by cataract patients worldwide CATALYS® System Mobile Patient Bed now available, designed to ensure ... Devices, Ophthalmology, Product Launch Johnson & Johnson, Symfony, Toric lens, LipiScan, LipiFlow (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Stryker Receives US FDA HDE Approval ror the Neuroform Atlas(TM) Stent System to Treat Wide Neck Aneurysms
KALAMAZOO, Michigan, USA, Nov. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Stryker Corporation announced today that the U.S. Food and Drug Administration has approved the Neuroform Atlas™ Stent System for marketing under a humanitarian device exe... Devices, Interventional, FDA Stryker, Neuroform Atlas, intracranial aneurysm, embolic coil (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Medical Devices Companies Unveils State of the Art "Engineering Studio" at Texas Medical Center to Accelerate Medical Devices Development
Center for Device Innovation @ Texas Medical Center to be Led by Acclaimed Surgeon and Entrepreneur Billy Cohn, M.D. HOUSTON, Nov. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Medical Devices Companies (JJMDC)* today opened th... Devices Johnson & Johnson, Johnson & Johnson Medical Devices Companies (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Ionis earns $5 million license fee from Dynacure CARLSBAD, Calif. and STRASBOURG, France, Nov. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS... Biopharmaceuticals, Licensing Ionis Pharmaceuticals, Dynacure, centronuclear myopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years DARMSTADT, Ge... Biopharmaceuticals, Neurology, Regulatory Merck, Cladribine, MAVENCLAD, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
ZURICH, November 9, 2017 -- (Healthcare Sales & Marketing Network) -- Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co.... Biopharmaceuticals, Neurology Neurimmune, Ono Pharmaceutical, Reverse Translational Medicine, aducanumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2017 Category: Pharmaceuticals Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D. on new steps to improve FDA review of shared Risk Evaluation and Mitigation Strategies to improve generic drug access
SILVER SPRING, Md., Nov. 8, 2017 -- (Healthcare Sales & Marketing Network) -- To manage the risks associated with drugs, the FDA employs a range of tools. For drugs that are associated with serious risks, the FDA can require drug makers to develop a Risk E... Biopharmaceuticals, Generics, FDA U.S. Food and Drug Administration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2017 Category: Pharmaceuticals Source Type: news

Geistlich Pharma North America, Inc. has New Vice President of Scientific and Clinical Affairs
PRINCETON, N.J., Nov. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Geistlich Pharma North America, Inc. announces that Fotinos (Foti) S. Panagakos, DMD, PhD, is joining the Geistlich U.S. leadership team as Vice President of Scientific and Clinica... Devices, Regenerative Medicine, Dental, Personnel Geistlich Pharma, Bio-Oss Collagen, Mucograft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2017 Category: Pharmaceuticals Source Type: news

Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Taltz also demonstrated improvements in key secondary measures, including skin clearance, at 52 weeks INDIANAPOLIS, Nov. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoria... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Psoriatic Arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2017 Category: Pharmaceuticals Source Type: news

New Clinical Data and Insurance Coverage Support Mederi's Stretta Therapy for GERD
RCT shows Stretta wins over PPI, and new coverage policy issued by Capital Blue Cross in PA NORWALK, Conn., Nov. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Mederi is pleased to announce publication of a new randomized, controlled trial as wel... Devices, Gastroenterology, Reimbursement Mederi Therapeutics, Stretta Therapy, Gastroesophageal Reflux Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2017 Category: Pharmaceuticals Source Type: news